AstraZeneca is in talks with US rival Bristol Myers Squibb about a potential merger that could form one of the world's largest pharmaceutical companies valued at nearly $400 billion. The discussions have been ongoing for several months and may conclude soon, though the deal could also be delayed or fall through. This move follows AstraZeneca's recent strong performance driven by cancer and rare disease drugs, with cancer treatments alone expected to generate $25 billion in sales by 2025. The merger would mark a significant consolidation in the pharma industry, coming about 12 years after AstraZeneca resisted a takeover attempt by Pfizer.
UK pharmaceutical company AstraZeneca is in talks to merge with US rival Bristol Myers Squibb, potentially forming a combined entity valued at around $400 billion. The merger would be one of the largest in history, combining AstraZeneca's global reac...
AstraZeneca disclosed that its Phase-3 trial for Wainua, a treatment for amyloid cardiomyopathy, failed to meet its primary endpoint, causing its stock to drop 5.7% on July 9, 2026. Following this, Pomerantz LLP announced an investigation into whethe...
